Repligen Corp.

RGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $28.4M $11.7M $9.3M $8.2M $16.1M $14.2M $-1.6M $-4.1M
Depreciation & Amortization $10.5M $5.3M $4.6M $4.0M $3.1M $3.5M $1.7M $1.4M
Depreciation $4.2M $3.3M $3.0M $2.6M $2.1M $2.5M $1.5M
Amortization $6.2M $2.1M $1.6M $1.4M $1.0M $1.0M $179.0K
Stock-Based Compensation $6.7M $4.6M $3.6M $1.8M $1.1M $1.0M $1.0M $1.0M
Net Cash from Operating Activities $17.5M $7.5M $15.1M $18.4M $25.9M $13.4M $3.2M $-2.4M
Investing Activities
Capital Expenditures $5.5M $4.3M $2.6M $5.6M $4.6M $1.3M $524.7K $597.3K
Business Acquisitions $112.8M $44.6M $21.2M
Net Cash from Investing Activities $-98.7M $-49.2M $-17.9M $2.8M $-1.5M $9.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $129.9M $112.1M $2.5M $1.2M $-50.3K $11.6K
Net Change in Cash $51.1M $68.1M $18.7M $-4.5M $10.6M $18.0M $1.7M $7.5M
Free Cash Flow $12.0M $3.2M $12.4M $12.8M $21.3M $12.2M $2.7M $-3.0M
← Newer Page 2 of 2 Older →